Baidu
map

Aliment Pharmacol Ther:泰戈拉赞vs.兰索拉唑治疗胃溃疡的效果

2021-07-26 MedSci原创 MedSci原创

泰戈拉赞是一种新型的钾竞争性阻酸剂,用于治疗酸相关疾病。近日,一项3期、双盲、主动对照、多中心研究评估了泰戈拉赞对胃溃疡患者的疗效和安全性是否不逊于兰索拉唑,研究结果已发表于Aliment Pharm

泰戈拉赞是一种新型的钾竞争性阻酸剂,用于治疗酸相关疾病。近日,一项3期、双盲、主动对照、多中心研究评估了泰戈拉赞对胃溃疡患者的疗效和安全性是否不逊于兰索拉唑,研究结果已发表于Aliment Pharmacol Ther。

研究纳入了306名胃溃疡患者,随机分配到三个治疗组:泰戈拉赞50毫克、泰戈拉赞100毫克和兰索拉唑30毫克,每天一次,为期4或8周。主要终点是治疗开始后8周内经内窥镜检查确认溃疡愈合的患者的累积比例。此外,研究人员还评估了治疗后的胃溃疡症状和安全性。

 

结果显示,第8周时,替戈拉赞50毫克的累积愈合率为94.8%(91/96),替戈拉赞100毫克为95.0%(94/99),兰索拉唑30毫克组为95.7%(89/93)。在第4周,各组的愈合率分别为90.6%(87/96)、91.9%(91/99)和89.2%(83/93)。按方案分析中,泰戈拉赞50毫克、泰戈拉赞100毫克和兰索拉唑30毫克的4周愈合率分别为95.4%(84/88)、94.6%(88/93)和92.9%(79/85)。两种剂量的泰戈拉赞在4周和8周时的溃疡愈合率均不逊于兰索拉唑。与药物相关的治疗性不良事件的发生率在各组之间没有差异。替戈拉赞治疗的患者血清胃泌素浓度的增加不比兰索拉唑治疗的患者高。

综上,该研究结果表明,在治疗胃溃疡方面,泰戈拉赞50或100毫克并不逊于兰索拉唑30毫克,每日一次。

 

原始出处:

 

Yu Kyung Cho, et al.,Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther. 2020 Sep;52(5):789-797. doi: 10.1111/apt.15865. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1241157, encodeId=a350124115e09, content=<a href='/topic/show?id=c5cf10460450' target=_blank style='color:#2F92EE;'>#替戈拉生#</a>vs.<a href='/topic/show?id=b733299e073' target=_blank style='color:#2F92EE;'>#兰索拉唑#</a>,泰戈拉赞翻译的不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104604, encryptionId=c5cf10460450, topicName=替戈拉生), TopicDto(id=29970, encryptionId=b733299e073, topicName=兰索拉唑)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Fri Aug 26 14:34:13 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996418, encodeId=6cba19964181e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 20 09:21:44 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908648, encodeId=a47a1908648b7, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 04 05:21:44 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787732, encodeId=bec51e87732e6, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 18 22:21:44 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788438, encodeId=28b11e8843871, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Feb 26 20:21:44 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352645, encodeId=eeea135264512, content=<a href='/topic/show?id=3287832083c' target=_blank style='color:#2F92EE;'>#胃溃疡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83208, encryptionId=3287832083c, topicName=胃溃疡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 28 03:21:44 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047406, encodeId=beb0104e406a1, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 15:21:44 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
    2022-08-26 小小医者

    #替戈拉生#vs.#兰索拉唑#,泰戈拉赞翻译的不好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1241157, encodeId=a350124115e09, content=<a href='/topic/show?id=c5cf10460450' target=_blank style='color:#2F92EE;'>#替戈拉生#</a>vs.<a href='/topic/show?id=b733299e073' target=_blank style='color:#2F92EE;'>#兰索拉唑#</a>,泰戈拉赞翻译的不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104604, encryptionId=c5cf10460450, topicName=替戈拉生), TopicDto(id=29970, encryptionId=b733299e073, topicName=兰索拉唑)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Fri Aug 26 14:34:13 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996418, encodeId=6cba19964181e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 20 09:21:44 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908648, encodeId=a47a1908648b7, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 04 05:21:44 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787732, encodeId=bec51e87732e6, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 18 22:21:44 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788438, encodeId=28b11e8843871, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Feb 26 20:21:44 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352645, encodeId=eeea135264512, content=<a href='/topic/show?id=3287832083c' target=_blank style='color:#2F92EE;'>#胃溃疡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83208, encryptionId=3287832083c, topicName=胃溃疡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 28 03:21:44 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047406, encodeId=beb0104e406a1, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 15:21:44 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
    2022-01-20 yb6560
  3. [GetPortalCommentsPageByObjectIdResponse(id=1241157, encodeId=a350124115e09, content=<a href='/topic/show?id=c5cf10460450' target=_blank style='color:#2F92EE;'>#替戈拉生#</a>vs.<a href='/topic/show?id=b733299e073' target=_blank style='color:#2F92EE;'>#兰索拉唑#</a>,泰戈拉赞翻译的不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104604, encryptionId=c5cf10460450, topicName=替戈拉生), TopicDto(id=29970, encryptionId=b733299e073, topicName=兰索拉唑)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Fri Aug 26 14:34:13 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996418, encodeId=6cba19964181e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 20 09:21:44 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908648, encodeId=a47a1908648b7, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 04 05:21:44 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787732, encodeId=bec51e87732e6, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 18 22:21:44 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788438, encodeId=28b11e8843871, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Feb 26 20:21:44 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352645, encodeId=eeea135264512, content=<a href='/topic/show?id=3287832083c' target=_blank style='color:#2F92EE;'>#胃溃疡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83208, encryptionId=3287832083c, topicName=胃溃疡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 28 03:21:44 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047406, encodeId=beb0104e406a1, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 15:21:44 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1241157, encodeId=a350124115e09, content=<a href='/topic/show?id=c5cf10460450' target=_blank style='color:#2F92EE;'>#替戈拉生#</a>vs.<a href='/topic/show?id=b733299e073' target=_blank style='color:#2F92EE;'>#兰索拉唑#</a>,泰戈拉赞翻译的不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104604, encryptionId=c5cf10460450, topicName=替戈拉生), TopicDto(id=29970, encryptionId=b733299e073, topicName=兰索拉唑)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Fri Aug 26 14:34:13 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996418, encodeId=6cba19964181e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 20 09:21:44 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908648, encodeId=a47a1908648b7, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 04 05:21:44 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787732, encodeId=bec51e87732e6, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 18 22:21:44 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788438, encodeId=28b11e8843871, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Feb 26 20:21:44 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352645, encodeId=eeea135264512, content=<a href='/topic/show?id=3287832083c' target=_blank style='color:#2F92EE;'>#胃溃疡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83208, encryptionId=3287832083c, topicName=胃溃疡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 28 03:21:44 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047406, encodeId=beb0104e406a1, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 15:21:44 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
    2022-04-18 jj000001
  5. [GetPortalCommentsPageByObjectIdResponse(id=1241157, encodeId=a350124115e09, content=<a href='/topic/show?id=c5cf10460450' target=_blank style='color:#2F92EE;'>#替戈拉生#</a>vs.<a href='/topic/show?id=b733299e073' target=_blank style='color:#2F92EE;'>#兰索拉唑#</a>,泰戈拉赞翻译的不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104604, encryptionId=c5cf10460450, topicName=替戈拉生), TopicDto(id=29970, encryptionId=b733299e073, topicName=兰索拉唑)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Fri Aug 26 14:34:13 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996418, encodeId=6cba19964181e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 20 09:21:44 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908648, encodeId=a47a1908648b7, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 04 05:21:44 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787732, encodeId=bec51e87732e6, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 18 22:21:44 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788438, encodeId=28b11e8843871, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Feb 26 20:21:44 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352645, encodeId=eeea135264512, content=<a href='/topic/show?id=3287832083c' target=_blank style='color:#2F92EE;'>#胃溃疡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83208, encryptionId=3287832083c, topicName=胃溃疡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 28 03:21:44 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047406, encodeId=beb0104e406a1, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 15:21:44 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1241157, encodeId=a350124115e09, content=<a href='/topic/show?id=c5cf10460450' target=_blank style='color:#2F92EE;'>#替戈拉生#</a>vs.<a href='/topic/show?id=b733299e073' target=_blank style='color:#2F92EE;'>#兰索拉唑#</a>,泰戈拉赞翻译的不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104604, encryptionId=c5cf10460450, topicName=替戈拉生), TopicDto(id=29970, encryptionId=b733299e073, topicName=兰索拉唑)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Fri Aug 26 14:34:13 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996418, encodeId=6cba19964181e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 20 09:21:44 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908648, encodeId=a47a1908648b7, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 04 05:21:44 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787732, encodeId=bec51e87732e6, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 18 22:21:44 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788438, encodeId=28b11e8843871, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Feb 26 20:21:44 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352645, encodeId=eeea135264512, content=<a href='/topic/show?id=3287832083c' target=_blank style='color:#2F92EE;'>#胃溃疡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83208, encryptionId=3287832083c, topicName=胃溃疡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 28 03:21:44 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047406, encodeId=beb0104e406a1, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 15:21:44 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1241157, encodeId=a350124115e09, content=<a href='/topic/show?id=c5cf10460450' target=_blank style='color:#2F92EE;'>#替戈拉生#</a>vs.<a href='/topic/show?id=b733299e073' target=_blank style='color:#2F92EE;'>#兰索拉唑#</a>,泰戈拉赞翻译的不好, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104604, encryptionId=c5cf10460450, topicName=替戈拉生), TopicDto(id=29970, encryptionId=b733299e073, topicName=兰索拉唑)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Fri Aug 26 14:34:13 CST 2022, time=2022-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996418, encodeId=6cba19964181e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 20 09:21:44 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908648, encodeId=a47a1908648b7, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Feb 04 05:21:44 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787732, encodeId=bec51e87732e6, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Apr 18 22:21:44 CST 2022, time=2022-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788438, encodeId=28b11e8843871, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sat Feb 26 20:21:44 CST 2022, time=2022-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352645, encodeId=eeea135264512, content=<a href='/topic/show?id=3287832083c' target=_blank style='color:#2F92EE;'>#胃溃疡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83208, encryptionId=3287832083c, topicName=胃溃疡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 28 03:21:44 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047406, encodeId=beb0104e406a1, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Mon Jul 26 15:21:44 CST 2021, time=2021-07-26, status=1, ipAttribution=)]
    2021-07-26 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

相关资讯

西格列汀和兰索拉唑组合有助于1型糖尿病患者

桑福德项目的研究者在临床试验中建立个一个里程碑,该项试验是验证两种药物的混合是否能有助于1型糖尿病人,在不使用或少使用胰岛素的情况下,使患者血糖水平保持在可控范围之内。在需要完成I期临床试验的全部患者中,都发生了被称之为“胰腺修复”的反应。在“胰腺修复”试验中,对两种FDA批准的药物——西格列汀和兰索拉唑潜在的临床效益进行了评估。试验需要54名参与者完成一项持续24个月的研究,其中有36名患者服用

GUT:沃诺拉赞(vonoprazan)vs.兰索拉唑的对照研究!

近期,一项发表在杂志GUT上的研究评估了与兰索拉唑相比,沃诺拉赞(vonoprazan)用于二次预防非甾体抗炎药(NSAID)诱导的消化性溃疡(PU)的非劣性以及其延长使用期间的安全性。此项研究为3期,为期24周的多中心随机双盲(DB)主动对照研究,随后是门诊3期患者,为期≥28周的多中心单盲平行组延伸研究(EXT) (n = 642),均接受长期NSAID治疗且有PU复发风险。患者接受沃诺拉赞(

GUT:复发性特发性胃十二指肠溃疡出血的治疗

研究认为,对于幽门螺杆菌阴性的特发性溃疡出血患者,兰索拉唑和法莫替丁对反复出血的预防效果相当

Gut:兰索拉唑和法莫替丁在预防复发性特发性胃十二指肠溃疡出血方向的效果

有幽门螺杆菌阴性特发性出血性溃疡病史的患者出现复发性溃疡并发症的风险较高。研究假设质子泵抑制剂(兰索拉唑)优于组胺2受体拮抗剂(法莫替丁),可预防此类患者的复发性溃疡出血。

Baidu
map
Baidu
map
Baidu
map